Medexus Pharmaceuticals (TSX:MDP) Other Long Term Assets: C$15.3 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:MDP Medexus Pharmaceuticals Inc TSX:MDP
53 GF Score
Price C$5.37
GF Value C$2.04
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Medexus Pharmaceuticals Other Long Term Assets?

Medexus Pharmaceuticals TSX:MDP +1.32% 53 Other Long Term Assets is C$15.3 Mil as of Jun. 2026. GuruFocus rates TSX:MDP with a GF Score™ of 53/100 and a GF Value™ of C$2.04 (Significantly Overvalued). The stock has 5 warning signs investors should review.

Medexus Pharmaceuticals's other long-term assets for the quarter that ended in Jun. 2026 was C$15.3 Mil.

Medexus Pharmaceuticals's quarterly other long-term assets increased from Dec. 2025 (C$13.2 Mil) to Mar. 2026 (C$14.5 Mil) and increased from Mar. 2026 (C$14.5 Mil) to Jun. 2026 (C$15.3 Mil).

Medexus Pharmaceuticals's annual other long-term assets increased from Mar. 2024 (C$10.9 Mil) to Mar. 2025 (C$12.9 Mil) and increased from Mar. 2025 (C$12.9 Mil) to Mar. 2026 (C$14.5 Mil).

Medexus Pharmaceuticals Other Long Term Assets Historical Data

* Premium members only.

The historical data trend for Medexus Pharmaceuticals's Other Long Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medexus Pharmaceuticals Other Long Term Assets Chart

Medexus Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Long Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.08 9.31 10.89 12.89 14.54

Medexus Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Long Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.63 12.86 13.19 14.54 15.32
TSX:MDP
53GF Score
Medexus Pharmaceuticals Inc TSX:MDP
Other Long Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medexus Pharmaceuticals Other Long Term Assets Calculation

GuruFocus lists Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets under the "Total Long-Term Assets" section.

Other Long Term Assets includes following items:
Investment in Properties
Non-current Accounts Receivable
Non-current Note Receivables
Non-current Deferred Assets
Non-current Prepaid Assets
Defined Pension Benefit
Other (too numerous to list)
Some companies can do choose to report each of these items separately. Yet, there are a variety of Other Long Term Assets which are simply too numerous to list.

Frequently Asked Questions Learn more about Other Long Term Assets →
What does a Other Long Term Assets of C$15.3 Mil mean?
Medexus Pharmaceuticals (TSX:MDP) has a Other Long Term Assets of C$15.3 Mil as of Jun. 2026. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Medexus Pharmaceuticals and its competitors.
Is Medexus Pharmaceuticals' Other Long Term Assets too high?
Medexus Pharmaceuticals' current Other Long Term Assets is C$15.3 Mil. Overall, Medexus Pharmaceuticals has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medexus Pharmaceuticals' Other Long Term Assets compare to ZTS?
Medexus Pharmaceuticals' Other Long Term Assets of C$15.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long Term Assets for a Drug Manufacturers company?
A good Other Long Term Assets depends on the Drug Manufacturers industry context. However, Other Long Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long Term Assets mean?
A high Other Long Term Assets can signal that a stock is expensive relative to its fundamentals. Other long-term assets as record on a company's balance sheet not categorized as standard assets. View historical data on Medexus Pharmaceuticals and its competitors. Medexus Pharmaceuticals's current Other Long Term Assets is C$15.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medexus Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Medexus Pharmaceuticals (TSX:MDP) is currently considered Significantly Overvalued. The stock's GF Value™ is C$2.04, compared to a current price of C$5.37 — trading 163.2% above its estimated fair value. The current Other Long Term Assets is C$15.3 Mil. Medexus Pharmaceuticals' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long Term Assets calculated?
Other Long Term Assets is calculated from a company's financial statements. For Medexus Pharmaceuticals (TSX:MDP), the current Other Long Term Assets is C$15.3 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medexus Pharmaceuticals (TSX:MDP) Overvalued in 2026?

Based on GuruFocus' analysis, Medexus Pharmaceuticals stock appears to be overvalued. The current stock price of C$5.37 is trading 163.2% above its estimated GF Value™ of C$2.04. GuruFocus considers Medexus Pharmaceuticals to be Significantly Overvalued.

Key valuation signals for TSX:MDP:

  • Other Long Term Assets: C$15.3 Mil
  • GF Value™: C$2.04 vs. price of C$5.37 (163.2% above fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the TSX:MDP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medexus Pharmaceuticals Business Description

Other Exchanges MEDXF:USAP731:Germany
Address 10 King Street East, Suite 600, Toronto, ON, CAN, M5C 1C3
Medexus Pharmaceuticals Inc is a specialty pharmaceutical company with a powerful North American commercial platform and a growing portfolio of inventive and rare disease treatment solutions. The company's focus is on the therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Medexus products are generally sold in North America to wholesalers, distributors, government agencies, healthcare facilities and specialty pharmacies.
53GF Score

Get the complete analysis for TSX:MDP

Other Long Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$5.37
Price
C$2.04
GF Value